



MELIOR DISCOVERY ENTERS NEW PHARMACEUTICAL COLLABORATION

Melior to Apply Its Unique *theraTRACE*SM Discovery Platform to Identify Potential New Indications for Multiple Drug Compounds

EXTON, PA, August 2, 2007 – Melior Discovery, Inc. today announced that it has signed an agreement with Johnson & Johnson Pharmaceutical Research & Development, L.L.C. (J&JPRD) to apply Melior's *theraTRACE*SM indications discovery platform to identify possible new indications for multiple J&JPRD drug candidates. Financial terms were not disclosed.

Melior's *theraTRACE* platform is a comprehensive, multiplexed set of integrated *in vivo* models designed to systematically and rapidly identify previously unknown applications for pharmaceutical compounds. It can be applied to discovery, development stage and marketed agents and has already identified novel indications for a number of development stage drugs.

"This agreement presents a significant opportunity for Melior to deliver value through the application of our unique *in vivo* testing platform to a range of pre-clinical and development stage compounds," said Andrew Reaume, Ph.D., President and CEO of Melior. "Our *theraTRACE* indications discovery platform is already proving its value in our existing collaborations with Merck and Pfizer, as well as in screening for our own drug development efforts. We are delighted to be working with J&JPRD, and we look forward to a productive collaboration."

Melior's *theraTRACE* platform is designed to systematically test the potential efficacy of compounds across a large number of disease models rapidly and efficiently, using the same high quality *in vivo* models developed by leading pharmaceutical researchers to determine whether a drug candidate demonstrates sufficient efficacy to merit advancement into clinical development. Melior's proprietary multiplexed approach integrates multiple *in vivo* models and reduces the time, amount of test compound and number of test subjects needed, while also reducing the number of false positive results. As a result, Melior's platform provides major improvements in efficiency and effectiveness and a reduction in the overall cost of the new indications discovery effort.

About Melior Discovery

Melior Discovery is leading the transformation of pharmaceutical drug repositioning with its proprietary *theraTRACE* platform of multiple integrated *in vivo* models. Melior is using this unique capability to assist pharmaceutical and biotechnology partners in realizing the full value of their pipeline assets and to build an internal pipeline of development candidates. Dr. Christopher Lipinski, a well-known research pioneer who was recently named one of the top 10 most influential people in the pharmaceutical industry, works closely with Melior in the development of its technology and identification of drug candidates.



For more information, visit www.meliordiscovery.com or call Dr. Andrew Reaume, President and CEO of Melior.

Contacts:

Melior Discovery
Andrew Reaume
President & CEO
(610) 280-0633
areaume@meliordiscovery.com

Media:

GendeLLindheim BioCom Partners
Barbara Lindheim
(212) 918-4650